856MO A randomized phase II study of concurrent vs. sequential pembrolizumab with chemoradiation (CRT) in locally advanced head and neck cancer (LA HNSCC): 4-year results and tumor-immune microenvironment analysis
Dan P. Zandberg, D.A. Clump, Brian R. Isett, Riyue Bao, H. Wang, L. Vujanovic, Haiyan Li, James Ohr, Moon J. Fenton, Heath D. Skinner, Raja R. Seethala, Simion I. Chiosea, Bennett Jonathan, Julie E. Bauman, R. Ferris
Topics & Concepts
MedicinePembrolizumabInternal medicineUnivariate analysisTumor microenvironmentHead and neck cancerProgression-free survivalCD8GastroenterologyOncologyImmune systemPhases of clinical researchCancerUrologyNuclear medicineImmunotherapyChemotherapyMultivariate analysisImmunologyCancer Immunotherapy and BiomarkersHead and Neck Cancer StudiesLung Cancer Diagnosis and Treatment